141 related articles for article (PubMed ID: 19636005)
1. The endogenous erythropoietin in correlation with other erythrocytic parameters in patients with head and neck squamous cell carcinoma treated with platinum-based induction chemotherapy.
Leś D; Saduś-Wojciechowska M; Rutkowski T; Wygoda A; Składowski K
Contemp Oncol (Pozn); 2019; 23(3):178-182. PubMed ID: 31798335
[TBL] [Abstract][Full Text] [Related]
2. Use of platelet and erythroid growth factors during induction chemotherapy for acute lymphoblastic leukaemia in a Jehovah's Witness.
Arora N; Gupta A; Li HC; Sadeghi N
BMJ Case Rep; 2018 Dec; 11(1):. PubMed ID: 30567199
[TBL] [Abstract][Full Text] [Related]
3. The impact of anaemia on treatment outcome in patients with squamous cell carcinoma of anal canal and anal margin.
Oblak I; Cesnjevar M; Anzic M; Hadzic JB; Ermenc AS; Anderluh F; Velenik V; Jeromen A; Korosec P
Radiol Oncol; 2016 Mar; 50(1):113-20. PubMed ID: 27069457
[TBL] [Abstract][Full Text] [Related]
4. Functional EpoR pathway utilization is not detected in primary tumor cells isolated from human breast, non-small cell lung, colorectal, and ovarian tumor tissues.
Patterson SD; Rossi JM; Paweletz KL; Fitzpatrick VD; Begley CG; Busse L; Elliott S; McCaffery I
PLoS One; 2015; 10(3):e0122149. PubMed ID: 25807104
[TBL] [Abstract][Full Text] [Related]
5. Myeloid toxicity of cancer treatment.
Kurtin S
J Adv Pract Oncol; 2012 Jul; 3(4):209-24. PubMed ID: 25031949
[TBL] [Abstract][Full Text] [Related]
6. Use of high-dose erythropoietin for repair after injury: A comparison of outcomes in heart and kidney.
Gobe GC; Morais C; Vesey DA; Johnson DW
J Nephropathol; 2013 Jul; 2(3):154-65. PubMed ID: 24475445
[TBL] [Abstract][Full Text] [Related]
7. Alternatives to blood transfusion.
Spahn DR; Goodnough LT
Lancet; 2013 May; 381(9880):1855-65. PubMed ID: 23706802
[TBL] [Abstract][Full Text] [Related]
8. Functional significance of erythropoietin in renal cell carcinoma.
Morais C; Johnson DW; Vesey DA; Gobe GC
BMC Cancer; 2013 Jan; 13():14. PubMed ID: 23305401
[TBL] [Abstract][Full Text] [Related]
9. Erythropoietin or darbepoetin for patients with cancer.
Tonia T; Mettler A; Robert N; Schwarzer G; Seidenfeld J; Weingart O; Hyde C; Engert A; Bohlius J
Cochrane Database Syst Rev; 2012 Dec; 12(12):CD003407. PubMed ID: 23235597
[TBL] [Abstract][Full Text] [Related]
10. Characterization of the erythropoietin/erythropoietin receptor axis in a rat model of liver damage and cholangiocarcinoma development.
Moriconi F; Ramadori P; Schultze FC; Blaschke M; Amanzada A; Khan S; Ramadori G
Histochem Cell Biol; 2013 Mar; 139(3):473-85. PubMed ID: 23052842
[TBL] [Abstract][Full Text] [Related]
11. The effect of erythropoietin on normal and neoplastic cells.
Elliott S; Sinclair AM
Biologics; 2012; 6():163-89. PubMed ID: 22848149
[TBL] [Abstract][Full Text] [Related]
12. Erythropoietin neuroprotection with traumatic brain injury.
Ponce LL; Navarro JC; Ahmed O; Robertson CS
Pathophysiology; 2013 Feb; 20(1):31-8. PubMed ID: 22421507
[TBL] [Abstract][Full Text] [Related]
13. Effects of erythropoietin receptors and erythropoiesis-stimulating agents on disease progression in cancer.
Aapro M; Jelkmann W; Constantinescu SN; Leyland-Jones B
Br J Cancer; 2012 Mar; 106(7):1249-58. PubMed ID: 22395661
[TBL] [Abstract][Full Text] [Related]
14. Transfusion risk in cancer patients with chemotherapy-induced anemia when initiating darbepoetin alfa therapy at a baseline hemoglobin level of <9 g/dL versus 9 to <10 g/dL versus ≥ 10 g/dL: an exploratory analysis of a phase 3 trial.
Canon JL; Vansteenkiste J; Hedenus M; Gascon P; Bokemeyer C; Ludwig H; Vermorken J; Legg J; Pujol B; Bridges K
Med Oncol; 2012 Sep; 29(3):2291-9. PubMed ID: 22081263
[TBL] [Abstract][Full Text] [Related]
15. Randomized trial comparing dose reduction and growth factor supplementation for management of hematological side effects in HIV/hepatitis C virus patients receiving pegylated-interferon and ribavirin.
Talal AH; Liu RC; Zeremski M; Dimova R; Dove L; Pearce D; Hassanein T; Doonquah L; Aboulafia D; Rodriguez J; Bonilla H; Galpin J; Aberg JA; Johnston B; Glesby MJ; Jacobson IM
J Acquir Immune Defic Syndr; 2011 Nov; 58(3):261-8. PubMed ID: 21876446
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of oral lactoferrin supplementation in combination with rHuEPO-beta for the treatment of anemia in advanced cancer patients undergoing chemotherapy: open-label, randomized controlled study.
Macciò A; Madeddu C; Gramignano G; Mulas C; Sanna E; Mantovani G
Oncologist; 2010; 15(8):894-902. PubMed ID: 20647390
[TBL] [Abstract][Full Text] [Related]
17. Erythroid-stimulating agents in cancer therapy: potential dangers and biologic mechanisms.
Hadland BK; Longmore GD
J Clin Oncol; 2009 Sep; 27(25):4217-26. PubMed ID: 19636005
[TBL] [Abstract][Full Text] [Related]
18. Examining the involvement of erythropoiesis-stimulating agents in tumor proliferation (erythropoietin receptors, receptor binding, signal transduction), angiogenesis, and venous thromboembolic events.
Fandrey J; Dicato M
Oncologist; 2009; 14 Suppl 1():34-42. PubMed ID: 19762515
[TBL] [Abstract][Full Text] [Related]
19. Erythropoietin in cancer patients.
Glaspy JA
Annu Rev Med; 2009; 60():181-92. PubMed ID: 18980468
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
